4000-520-616
欢迎来到免疫在线!(蚂蚁淘生物旗下平台)  请登录 |  免费注册 |  询价篮
MedKoo(授权代理)
主营:主营:抗癌化学试剂和激酶抑制剂
咨询热线电话
4000-520-616
当前位置: 首页 > 产品中心 > peptide > MedKoo/Lificiguatfeatured/25mg/406116
商品详细MedKoo/Lificiguatfeatured/25mg/406116
MedKoo/Lificiguatfeatured/25mg/406116
MedKoo/Lificiguatfeatured/25mg/406116
商品编号: 406116
品牌: MedKoo
市场价: ¥3000.00
美元价: 1800.00
产地: 美国(厂家直采)
公司:
产品分类: 多肽合成
公司分类: peptide
联系Q Q: 3392242852
电话号码: 4000-520-616
电子邮箱: info@ebiomall.com
商品介绍

Lificiguat
featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#:406116

CAS#:170632-47-0

Description:Lificiguat, also known as YC-1, is a inhibitor of Hypoxia-inducible factor-1alpha (HIF-1alpha). YC-1 is widely used as a potent inhibitor of HIF-1alpha both in vitro and in vivo, and is also being developed as a novel anticancer drug. YC-1 effectively inhibits tumor invasion and metastasis, and imply that YC-1 is worth while to further develop as a multipurpose anticancer drug.

Price and Availability

SizePriceShipping out timeQuantity
25mgUSD 150Same day
50mgUSD 250Same day
100mgUSD 450Same day
500mgUSD 1750Same day
1gUSD 2250Same day
2gUSD 3650Same day
5gUSD 46502 Weeks
10gUSD 69502 Weeks
Inquire bulk and customized quantity

Pricing updated 2021-01-23.Prices are subject to change without notice.

Lificiguat, purity > 98%, is in stock. The same day shipping after order is received.

Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 406116Name: LificiguatCAS#: 170632-47-0Chemical Formula: C19H16N2O2Exact Mass: 304.12118Molecular Weight: 304.34Elemental Analysis: C, 74.98; H, 5.30; N, 9.20; O, 10.51

Synonym:YC1; YC 1; YC-1; Lificiguat.

IUPAC/Chemical Name:5-​[1-​(phenylmethyl)-​1H-​indazol-​3-​yl]-​2-​furanmethanol

InChi Key:OQQVFCKUDYMWGV-UHFFFAOYSA-N

InChi Code:InChI=1S/C19H16N2O2/c22-13-15-10-11-18(23-15)19-16-8-4-5-9-17(16)21(20-19)12-14-6-2-1-3-7-14/h1-11,22H,12-13H2

SMILES Code:OCC1=CC=C(C2=NN(CC3=CC=CC=C3)C4=C2C=CC=C4)O1

Technical Data

Appearance:
white solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Certificate of Analysis:
View CoA: current batch, Lot#A20T06K11

QC Data:
View QC data: current batch, Lot#A20T06K11

Safety Data Sheet (SDS):
View Safety Data Sheet (SDS)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:
2934.99.9001

Additional Information

References

1: Tsui L, Fong TH, Wang IJ. The effect of3-(5"-hydroxymethyl-2"-furyl)-1-benzylindazole (YC-1) on cell viabilityunder hypoxia. Mol Vis. 2013 Nov 16;19:2260-73. eCollection 2013. PubMedPMID: 24265542; PubMed Central PMCID: PMC3834593.

2: Carroll CE, Liang Y, Benakanakere I, Besch-Williford C, Hyder SM. Theanticancer agent YC-1 suppresses progestin-stimulated VEGF in breastcancer cells and arrests breast tumor development. Int J Oncol. 2013Jan;42(1):179-87. doi: 10.3892/ijo.2012.1675. Epub 2012 Oct 24. PubMedPMID: 23123638; PubMed Central PMCID: PMC3583650.

3: Tsui L, Fong TH, Wang IJ. YC-1 targeting of hypoxia-induciblefactor-1α reduces RGC-5 cell viability and inhibits cell proliferation.Mol Vis. 2012;18:1594-603. Epub 2012 Jun 15. PubMed PMID: 22736948;PubMed Central PMCID: PMC3380911.

4: Cheng Y, Li W, Liu Y, Cheng HC, Ma J, Qiu L. YC-1 exerts inhibitoryeffects on MDA-MB-468 breast cancer cells by targeting EGFR in vitro andin vivo under normoxic condition. Chin J Cancer. 2012 May;31(5):248-56.doi: 10.5732/cjc.011.10383. Epub 2012 Apr 13. PubMed PMID: 22507221;PubMed Central PMCID: PMC3777523.

5: Yan J, Zhou B, Taheri S, Shi H. Differential effects of HIF-1inhibition by YC-1 on the overall outcome and blood-brain barrier damagein a rat model of ischemic stroke. PLoS One. 2011;6(11):e27798. doi:10.1371/journal.pone.0027798. Epub 2011 Nov 16. PubMed PMID: 22110762;PubMed Central PMCID: PMC3218033.

6: Li Y, Zhao X, Tang H, Zhong Z, Zhang L, Xu R, Li S, Wang Y. Effectsof YC-1 on hypoxia-inducible factor 1 alpha in hypoxic human bladdertransitional carcinoma cell line T24 cells. Urol Int. 2012;88(1):95-101.doi: 10.1159/000331881. Epub 2011 Oct 25. PubMed PMID: 22041818.

7: Liu H, Li M, Wang P, Wang F. Blockade of hypoxia-inducible factor-1αby YC-1 attenuates interferon-γ and tumor necrosis factor-α-inducedintestinal epithelial barrier dysfunction. Cytokine. 2011Dec;56(3):581-8. doi: 10.1016/j.cyto.2011.08.023. Epub 2011 Sep 3.PubMed PMID: 21890376.

8: Feng Y, Zhu H, Ling T, Hao B, Zhang G, Shi R. Effects of YC-1targeting hypoxia-inducible factor 1 alpha in oesophageal squamouscarcinoma cell line Eca109 cells. Cell Biol Int. 2011 May;35(5):491-7.doi: 10.1042/CBI20090419. PubMed PMID: 20977428.

9: DeNiro M, Al-Halafi A, Al-Mohanna FH, Alsmadi O, Al-Mohanna FA.Pleiotropic effects of YC-1 selectively inhibit pathological retinalneovascularization and promote physiological revascularization in amouse model of oxygen-induced retinopathy. Mol Pharmacol. 2010Mar;77(3):348-67. doi: 10.1124/mol.109.061366. Epub 2009 Dec 14. PubMedPMID: 20008515.

10: Moon SY, Chang HW, Roh JL, Kim GC, Choi SH, Lee SW, Cho KJ, Nam SY,Kim SY. Using YC-1 to overcome the radioresistance of hypoxic cancercells. Oral Oncol. 2009 Oct;45(10):915-9. doi:10.1016/j.oraloncology.2009.04.005. Epub 2009 May 19. PubMed PMID:19457706.

11: Wang SX, Pei ZZ, Wu XH, Li JK, Yang YJ. [Effect of YC-1 on HIF-1alpha and VEGF expression in human hepatocarcinoma cell lines]. ZhonghuaGan Zang Bing Za Zhi. 2009 Apr;17(4):308-9. Chinese. PubMed PMID:19403034.

12: Li SH, Shin DH, Chun YS, Lee MK, Kim MS, Park JW. A novel mode ofaction of YC-1 in HIF inhibition: stimulation of FIH-dependent p300dissociation from HIF-1{alpha}. Mol Cancer Ther. 2008 Dec;7(12):3729-38.doi: 10.1158/1535-7163.MCT-08-0074. PubMed PMID: 19074848.

13: Song SJ, Chung H, Yu HG. Inhibitory effect of YC-1,3-(5"-hydroxymethyl-2"-furyl)-1-benzylindazole, on experimentalchoroidal neovascularization in rat. Ophthalmic Res. 2008;40(1):35-40.Epub 2007 Nov 20. PubMed PMID: 18032914.

14: Yeh WL, Lu DY, Lin CJ, Liou HC, Fu WM. Inhibition of hypoxia-inducedincrease of blood-brain barrier permeability by YC-1 through theantagonism of HIF-1alpha accumulation and VEGF expression. Mol Pharmacol.2007 Aug;72(2):440-9. Epub 2007 May 18. PubMed PMID: 17513385.

15: Shin DH, Kim JH, Jung YJ, Kim KE, Jeong JM, Chun YS, Park JW.Preclinical evaluation of YC-1, a HIF inhibitor, for the prevention oftumor spreading. Cancer Lett. 2007 Sep 18;255(1):107-16. Epub 2007 May14. PubMed PMID: 17502124.

16: Zhao Q, Du J, Gu H, Teng X, Zhang Q, Qin H, Liu N. Effects of YC-1on hypoxia-inducible factor 1-driven transcription activity, cellproliferative vitality, and apoptosis in hypoxic human pancreatic cancercells. Pancreas. 2007 Mar;34(2):242-7. PubMed PMID: 17312464.

17: Sun HL, Liu YN, Huang YT, Pan SL, Huang DY, Guh JH, Lee FY, Kuo SC,Teng CM. YC-1 inhibits HIF-1 expression in prostate cancer cells:contribution of Akt/NF-kappaB signaling to HIF-1alpha accumulationduring hypoxia. Oncogene. 2007 Jun 7;26(27):3941-51. Epub 2007 Jan 8.PubMed PMID: 17213816.

18: Du J, Zhao Q, Gu H, Teng XL, Qin H, Liu NZ. [Inhibitory effect ofYC-1 on induction of VEGF and GPI genes in hypoxic human pancreaticcancer cells]. Zhonghua Zhong Liu Za Zhi. 2006 Jul;28(7):486-9. Chinese.PubMed PMID: 17147109.

19: Lau CK, Yang ZF, Lam CT, Tam KH, Poon RT, Fan ST. Suppression ofhypoxia inducible factor-1alpha (HIF-1alpha) by YC-1 is dependent onmurine double minute 2 (Mdm2). Biochem Biophys Res Commun. 2006 Oct6;348(4):1443-8. Epub 2006 Aug 11. PubMed PMID: 16919599.

20: Yeo EJ, Ryu JH, Chun YS, Cho YS, Jang IJ, Cho H, Kim J, Kim MS, ParkJW. YC-1 induces S cell cycle arrest and apoptosis by activatingcheckpoint kinases. Cancer Res. 2006 Jun 15;66(12):6345-52. PubMed PMID:16778212.

品牌介绍
MedKoo 美帝药库公司以药物化学合成技术为核心,密切结合全球抗癌新药研发领域中的新技术、新理论、新趋势和新的发展方向,不断推出抗癌化合物新品种。 。 美帝药库MedKoo将在中国建立药物化学合成生产基地和多个现代化药物化合物存储仓库。 美帝药库的药物化合物来源于以下几个渠道:自主合成、委托化学合成、合作伙伴、和从国内外市场上选购。 MedKoo美帝药库的抗癌分子库 MedKoo的目标是打造全球规模最大、品种最多、类别最全和质量最好的小分子抗癌化合物库。MedKoo的抗癌药库将由下列5个分子库组成: (1)上市抗癌药库:该库将含有大约100个全球已批准上市的小分子抗癌化合物; (2)抗癌候选药物库:该分子库含有大约400个世界各国正在临床研究中抗癌小分子候选药物; (3)同系抗癌分子库:该分子库将含有多个化学结构类似或抗癌机制类似的分子包; (4)抗癌分子预制模块库:该库主要含有用于组建抗癌目标分子的分子模块包; (5)同位素标记抗癌分子库。